Frankfurt - Delayed Quote EUR

IGM Biosciences, Inc. (1K0.F)

1.0300

+0.0300

+(3.00%)

At close: May 16 at 3:48:54 PM GMT+2

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates

IGM Biosciences (IGMS) delivered earnings and revenue surprises of -109.76% and 91.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 days ago

IGMS
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

BTAI

IGMS
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

IGMS

PRAX
Promising US Penny Stocks To Watch In February 2025

As the U.S. stock market navigates a mixed trading environment with major indexes slipping after recent gains, investors are keenly observing opportunities that might arise from smaller segments of the market. Penny stocks, often representing smaller or newer companies, remain relevant for their potential to offer significant returns when backed by solid financials. In this article, we will explore several penny stocks that stand out due to their financial strength and growth potential,...

Simply Wall St. 2 months ago

BMEA

ANRO

IGMS
Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround

IGM Biosciences (IGMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 3 months ago

IGMS
IGM Biosciences downgraded to Hold from Buy at Jefferies

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all clinical development of drugs in its autoimmune franchise and said it is evaluating internal options and strategic alternatives with the goal of maximizing value for its shareholders. Following the announcement, the firm removed clinical program revenue from its model and lowered its view of platform value to $50M, mostly related to the still-ongoing Sanofi (S

TipRanks 4 months ago

IGMS

SNY

SNYNF
IGM Biosciences Shares Drop 68% as Company Halts Key Programs and Cuts Workforce

The company is reducing its workforce by 73% and evaluating strategic alternatives to preserve shareholder value.

GuruFocus.com 4 months ago

IGMS
IMG Biosciences enacts massive lay-offs after Phase I trial failure

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.

Clinical Trials Arena 4 months ago

IGMS
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory diseases, today announced a strategic update to halt further develop

GlobeNewswire 4 months ago

IGMS
IGM’s autoimmune pivot backfires as top drug disappoints in testing

The biotech will stop developing two drugs and lay off much of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

BioPharma Dive 4 months ago

IGMS
IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

IGM Biosciences ( NASDAQ:IGMS ) Third Quarter 2024 Results Key Financial Results Net loss: US$61.4m (flat on 3Q 2023...

Simply Wall St. 6 months ago

IGMS
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates

IGM Biosciences (IGMS) delivered earnings and revenue surprises of -23.17% and 123.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 6 months ago

IGMS
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies

GlobeNewswire 6 months ago

IGMS
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, IGM Biosciences...

Simply Wall St. 6 months ago

IGMS
IGM Biosciences to Present at Three Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences: Guggenheim Healthcare Innovation Conference on Monday, November 11 at 11:30 a.m. EST in BostonStifel Healthcare Conference on Tuesday, November 19 at 12:40 p.m. EST in New YorkJefferies London Healthcare Conference on Thursday, No

GlobeNewswire 6 months ago

IGMS
Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover

IGM stock crashed Tuesday after the biotech company scrapped development of a cancer drug and announced three of its executives stepped down.

Investor's Business Daily 7 months ago

IGMS
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

On Tuesday, IGM Biosciences Inc. (NASDAQ:IGMS) announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for autoimmune diseases. The company’s lead candidates include imvotamab, which is being developed for rheumatoid arthritis, systemic lupus erythematosus, and myositis, and IGM-2644, which is expected to enter a clinical study for generalized myasthenia gravis by the end of 2024. IGM to minimize future spending

Benzinga 7 months ago

IGMS
IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply

IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.

BioPharma Dive 7 months ago

IGMS

MRNA
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D., appointed as Chief Executive Officer and to Board of Directors – – Cash runway extended into 2027 – – Company to hold conference call and webcast today at 4:30 p.m. EDT – MOUNTAIN VIEW, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage

GlobeNewswire 7 months ago

IGMS
While shareholders of IGM Biosciences (NASDAQ:IGMS) are in the black over 1 year, those who bought a week ago aren't so fortunate

Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...

Simply Wall St. 7 months ago

IGMS

Performance Overview

Return	1K0.F	S&P 500 (^GSPC)
YTD	-82.83%	+1.30%
1-Year	-88.02%	+12.48%
3-Year	-92.95%	+48.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

IGM Biosciences, Inc. (1K0.F)

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Promising US Penny Stocks To Watch In February 2025

Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround

IGM Biosciences downgraded to Hold from Buy at Jefferies

IGM Biosciences Shares Drop 68% as Company Halts Key Programs and Cuts Workforce

IMG Biosciences enacts massive lay-offs after Phase I trial failure

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

IGM’s autoimmune pivot backfires as top drug disappoints in testing

IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

IGM Biosciences to Present at Three Upcoming Investor Conferences

Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover

IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO

IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

While shareholders of IGM Biosciences (NASDAQ:IGMS) are in the black over 1 year, those who bought a week ago aren't so fortunate

Performance Overview